GOSS
Gossamer Bio, Inc.3.5600
-0.2300-6.07%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
823.98MP/E (TTM)
-Basic EPS (TTM)
-0.69Dividend Yield
0%Recent Filings
8-K
Q3 loss widens; trials advance
Gossamer Bio reported Q3 net loss of $48.2M, up from $30.8M last year, as R&D expenses climbed to $45.5M amid Phase 3 progress. PROSERA PAH enrollment wrapped June; topline data due February 2026. First SERANATA PH-ILD site activated. Cash at $180M funds into 2027. Option to acquire Respira for 1.5M shares preserves liquidity.
10-Q
Q3 FY2025 results
Gossamer Bio posted Q3 revenue of $13.3M from Chiesi collaboration, up 40% y/y yet down from YTD peaks after upfront license recognition. R&D expenses jumped 31% y/y to $45.5M on seralutinib trials, plus $7.5M IPR&D hit for Prana merger option via stock issuance; operating loss widened to $49.1M from $33.9M y/y, with net loss at $48.2M versus $30.8M as other income dipped. Cash burned $123M in operating activities YTD, leaving $180.2M in cash and marketable securities against $198M 5% 2027 Notes (fair value $142.5M). EPS reconciles at -$0.21 on 228M shares. Chiesi funds 100% of revenue. Clinical delays threaten cash runway.
8-K
8-K
Gossamer Q2 loss, trials advance
Gossamer Bio reported Q2 2025 financials, posting a $38.3 million net loss amid $41.6 million R&D spend, down from last year's profit due to absent one-time license revenue, while holding $212.9 million in cash to fund operations into 2027. The company completed enrollment in the Phase 3 PROSERA trial for seralutinib in PAH, eyeing topline data in February 2026, and plans first site activations for the PH-ILD SERANATA study this Q4. Cash runway supports the pivot to commercialization with Chiesi.
10-Q
Q2 FY2025 results
Gossamer Bio's Q2 FY2025 revenue fell to $11.5M from $95.8M y/y, driven by the prior year's $88.8M license sale under the Chiesi deal, while collaborator revenue rose 62% y/y to $11.5M from ongoing R&D cost-sharing. Operating expenses climbed 15% y/y to $50.3M, mainly from $41.6M in seralutinib trials (up 28% y/y), yielding an operating loss of $38.8M versus $52.1M profit last year; net loss hit $38.3M or $(0.17) diluted EPS, consistent with 227M shares. Cash burn intensified with $86.8M used in operations (derived), leaving $212.9M in cash and securities against $198.0M in 5% convertible notes due 2027. The PROSERA Phase 3 trial wrapped enrollment, eyeing topline data in February 2026. Yet regulatory hurdles could delay seralutinib's path to approval.
CBIO
Crescent Biopharma, Inc.
12.92-0.29
GHRS
GH Research PLC
12.66+0.17
GLTO
Galecto, Inc.
30.00-1.60
GRI
GRI Bio, Inc.
0.48+0.00
GYRE
Gyre Therapeutics, Inc.
7.58+0.04
KROS
Keros Therapeutics, Inc.
21.53+0.30
PHAT
Phathom Pharmaceuticals, Inc.
15.24+0.55
PULM
Pulmatrix, Inc.
4.10-0.25
SVRA
Savara, Inc.
6.43-0.18
UPB
Upstream Bio, Inc.
29.32+2.12